Bioorg Med Chem Lett. 2015 Nov 17. pii: S0960-894X(15)30258-4. doi: 10.1016/j.bmcl.2015.11.050. [Epub ahead of print]
Ma, Z; Lin, DC; Sharma, R; Liu, J; Zhu, L; Li, AR; Kohn, T; Wang, Y; Liu, JJ; Bartberger, MD; Medina, JC; Zhuang, R; Li, L; Zhang, J; Luo, J; Wong, S; Tonn, GR; Houze, JB
Amgen Inc., South San Francisco, CA, USA.
As a follow-up to the GPR40 agonist AMG 837, which was evaluated in clinical trials for the treatment of type II diabetes, further optimization led to the discovery of AM-3189 (13k). AM-3189 is representative of a new class of compounds with minimal CNS penetration, superior pharmacokinetic properties and in vivo efficacy comparable to AMG 837.
The team at Ozgene has over two decades of experience creating customised knockout and knock-in mice for pivotal medical research globally. Over 400 scientific publications are based on research using Ozgene mice.